In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
Chuang
De-Maw
DM
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1363, USA. chuang@mail.nih.gov
Manji
Husseini K
HK
D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001921:Brain / Q000187:drug effects; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3 / Q000187:drug effects; D006801:Humans; D018020:Lithium Compounds / Q000627:therapeutic use*; D019636:Neurodegenerative Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D051381:Rats
D019208:Brain-Derived Neurotrophic Factor; D018020:Lithium Compounds; D018696:Neuroprotective Agents; D038362:Glycogen Synthase Kinase 3